TABLE 3.
Subgroup analysis of the top 10 specific risk signals in the younger age group (1–11 years) and older age group (12–17 years) for VEGFR-TKI.
| PT | ROR | 95% CI | Case reports (%) | |
|---|---|---|---|---|
| 1–11 (n = 194) | ||||
| drug intolerance | 43.95 | 26.10–74.01 | 16 | 8.25 |
| bone marrow failure | 26.19 | 15.38–44.58 | 15 | 7.73 |
| pancytopenia | 20.98 | 12.34–35.66 | 15 | 7.73 |
| skin toxicity | 252.87 | 136.88–467.13 | 14 | 7.22 |
| lymphadenopathy | 24.26 | 13.75–42.82 | 13 | 6.70 |
| ALT increased | 9.32 | 5.19–16.73 | 12 | 6.19 |
| pleural effusion | 18.87 | 9.93–35.83 | 10 | 5.15 |
| AST increased | 6.76 | 3.33–13.74 | 8 | 4.12 |
| hypothyroidism | 35.65 | 17.34–73.30 | 8 | 4.12 |
| PPES | 222.70 | 100.64–492.81 | 8 | 4.12 |
| 12–17 (n = 367) | ||||
| PPES | 324.26 | 201.59–521.57 | 33 | 8.99 |
| pneumothorax | 71.63 | 47.83–107.27 | 30 | 8.17 |
| diarrhoea | 5.54 | 3.76–8.16 | 28 | 7.63 |
| pyrexia | 2.33 | 1.52–3.59 | 22 | 5.99 |
| Rash | 2.60 | 1.67–4.04 | 21 | 5.72 |
| anaemia | 10.20 | 6.39–16.28 | 19 | 5.18 |
| febrile neutropenia | 10.07 | 6.23–16.26 | 18 | 4.90 |
| alopecia | 9.65 | 5.90–15.78 | 17 | 4.63 |
| Fatigue | 2.08 | 1.27–3.38 | 17 | 4.63 |
| hypertension | 4.93 | 2.88–8.44 | 14 | 3.81 |